- Conditions
- Breast Cancer
- Interventions
- vepdegestrant, PF-07220060
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 34
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–19
of 19
matching trials from the live ClinicalTrials.gov search.
- Conditions
- KRAS G12D Mutation, Advanced Solid Cancer
- Interventions
- ARV-806
- Drug
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 9 more
- Conditions
- Prostate Cancer Metastatic
- Interventions
- ARV-110
- Drug
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 54
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 51 more
- Conditions
- Breast Cancer
- Interventions
- Vepdegestrant, Palbociclib
- Drug
- Lead sponsor
- Arvinas Estrogen Receptor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 16
- States / cities
- Palo Alto, California • San Francisco, California • Santa Monica, California + 12 more
- Conditions
- Breast Cancer
- Interventions
- ARV-471, Abemaciclib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 23
- States / cities
- Palo Alto, California • San Francisco, California • Tampa, Florida + 11 more
- Conditions
- Healthy Participants
- Interventions
- vepdegestrant
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Miami, Florida • Miami Lakes, Florida • Orlando, Florida + 1 more
- Conditions
- Healthy
- Interventions
- [phenyl-14C]ARV-471, [oxoisoindolin-14C]ARV-471
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Breast Cancer
- Interventions
- Vepdegestrant (ARV-471/PF-07850327), Palbociclib, Letrozole
- Drug · Combination Product
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Plantation, Florida • Norfolk, Virginia
- Conditions
- Breast Cancer
- Interventions
- ARV-471 in combination with Everolimus
- Drug
- Lead sponsor
- Arvinas Estrogen Receptor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- San Diego, California • Santa Monica, California • Washington D.C., District of Columbia + 3 more
- Conditions
- Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
- Interventions
- ARV-393, Glofitamab
- Drug
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 10
- States / cities
- New Haven, Connecticut • Miami, Florida • Detroit, Michigan + 6 more
- Conditions
- Breast Cancer
- Interventions
- vepdegestrant, Samuraciclib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 17
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more
- Conditions
- Advanced Breast Cancer
- Interventions
- ARV-471, Fulvestrant
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 624 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 87
- States / cities
- Encinitas, California • Fountain Valley, California • Fresno, California + 69 more
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Bavdegalutamide, Abiraterone
- Drug
- Lead sponsor
- Arvinas Androgen Receptor, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 9
- States / cities
- Santa Monica, California • New Haven, Connecticut • Fort Myers, Florida + 6 more
- Conditions
- Healthy
- Interventions
- ARV-471, Rosuvastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy
- Interventions
- vepdegestrant, esomeprazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy
- Interventions
- single dose of vepdegestrant as tablet formulation (Treatment A), single dose of vepdegestrant as tablet formulation (Treatment B), single dose of vepdegestrant as tablet formulation (Treatment C)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Breast Cancer
- Interventions
- ARV-471, Ribociclib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 20
- States / cities
- Palo Alto, California • San Francisco, California • Tampa, Florida + 7 more
- Conditions
- Breast Cancer
- Interventions
- ARV-471, Anastrozole, Surgical resection of breast tumor
- Drug · Procedure
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 13
- States / cities
- Springdale, Arkansas • Los Angeles, California • Torrance, California + 10 more
- Conditions
- Advanced Solid Tumor
- Interventions
- ARV-6723, Pembrolizumab, SOC
- Drug
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 3
- States / cities
- Huntersville, North Carolina • San Antonio, Texas • Fairfax, Virginia